(Updating with background on Schering's HRT product Angeliq)
BERLIN (AFX) - Schering AG said it has launched its hormone therapy
once-a-week patch to treat menopausal symptoms, Climara Pro, in the US today
after receiving approval from the Food and Drug Administration last November.
Schering had previously said its planned to launch Climara Pro in January.
Climara Pro has an annual peak sales potential of 100 mln eur in the US.
Last week, Schering said it has decided to the delay the marketing of its
hormone replacement therapy product Angeliq in Europe until the end of this year
due to fears concerning HRT products.
Angeliq had in December 2002 already been approved in the Netherlands, and
had completed the EU's Mutual Recognition Procedure in July 2003.
newsdesk@afxnews.com
das/hjp |
Thread abonnieren
